Reuters logo
BRIEF-Novartis announces additional analyses from late-stage study on LEE011 plus letrozole
December 9, 2016 / 1:42 PM / a year ago

BRIEF-Novartis announces additional analyses from late-stage study on LEE011 plus letrozole

Dec 9 (Reuters) - Novartis AG

* Novartis says announced additional analyses from Phase III Monaleesa-2 study

* Novartis - findings demonstrate strength of LEE011 plus letrozole in first-line setting, showing treatment benefit was evident across all patient subgroups

* Novartis says analyses from the study show LEE011 plus letrozole significantly prolonged progression-free survival across pre-planned patient subgroups Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below